UBS Group AG - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 132 filers reported holding CTI BIOPHARMA CORP in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.3%.

Quarter-by-quarter ownership
UBS Group AG ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q1 2023$1,692,151
-69.6%
402,893
-56.5%
0.00%
-50.0%
Q4 2022$5,567,117
+562.8%
926,309
+542.1%
0.00%
Q3 2022$840,000
-49.3%
144,256
-48.0%
0.00%
-100.0%
Q2 2022$1,656,000
+2023.1%
277,500
+1558.3%
0.00%
Q1 2022$78,000
+680.0%
16,734
+316.6%
0.00%
Q4 2021$10,000
-23.1%
4,017
-6.1%
0.00%
Q3 2021$13,000
-23.5%
4,278
-36.6%
0.00%
Q2 2021$17,000
-41.4%
6,747
-32.3%
0.00%
Q1 2021$29,000
+107.1%
9,971
+133.1%
0.00%
Q4 2020$14,000
+40.0%
4,278
-12.0%
0.00%
Q3 2020$10,000
-66.7%
4,862
-81.2%
0.00%
Q2 2020$30,000
+87.5%
25,862
+46.4%
0.00%
Q1 2020$16,000
+6.7%
17,667
+87.9%
0.00%
Q4 2019$15,000
+400.0%
9,404
+130.7%
0.00%
Q3 2019$3,000
-57.1%
4,076
-50.2%
0.00%
Q2 2019$7,000
+16.7%
8,185
+38.0%
0.00%
Q1 2019$6,000
-75.0%
5,930
-81.7%
0.00%
Q4 2018$24,000
-57.1%
32,381
+25.5%
0.00%
Q3 2018$56,000
-44.6%
25,805
+26.5%
0.00%
Q2 2018$101,000
+71.2%
20,407
+34.7%
0.00%
Q1 2018$59,000
+96.7%
15,155
+35.6%
0.00%
Q4 2017$30,000
+30.4%
11,176
+55.2%
0.00%
Q3 2017$23,000
+64.3%
7,203
+66.0%
0.00%
Q2 2017$14,000
-30.0%
4,338
-9.9%
0.00%
Q1 2017$20,0004,8170.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q3 2022
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 6,535,674$27,449,8319.21%
Bleichroeder LP 3,893,730$16,353,6663.49%
AIGH Capital Management LLC 2,100,000$8,820,0003.25%
Ally Bridge Group (NY) LLC 550,000$2,310,0003.03%
Ghost Tree Capital, LLC 2,000,000$8,400,0002.48%
Bain Capital Life Sciences Investors, LLC 4,702,996$19,7532.47%
Altium Capital Management LP 850,000$3,570,0001.98%
Parkman Healthcare Partners LLC 1,753,630$7,365,2461.60%
BVF INC/IL 8,813,021$37,014,6881.35%
Sio Capital Management, LLC 526,239$2,210,2041.09%
View complete list of CTI BIOPHARMA CORP shareholders